Table 1.
Association between RPRM methylation of CGIs and clinicopathological features.
| Clinicopathological Features | n | Methylation of RPRM CGIs | p | |
|---|---|---|---|---|
| Low | High | |||
| Age (year; mean 60) | 77 | 0.021 | ||
| ≤60 | 43 | 23 (71.9%) | 20 (44.4%) | |
| >60 | 34 | 9 (28.1%) | 25 (55.6%) | |
| Tumor Size * | 76 | 0.586 | ||
| T1 + T2 | 58 | 23 (39.7%) | 35 (60.3%) | |
| T3 + T4 | 18 | 9 (50.0%) | 9 (50.0%) | |
| Lymph node metástasis * | 76 | 0.247 | ||
| No | 35 | 12 (34.3%) | 23 (65.7%) | |
| Yes | 41 | 20 (48.4%) | 21 (51.2%) | |
| TNM Stage * | 76 | 0.621 | ||
| I + II | 51 | 20 (39.2%) | 31 (60.8%) | |
| III + IV | 25 | 12 (48.0%) | 13 (52.0%) | |
| Elston Grade * | 75 | 0.239 | ||
| Well differentiated | 14 | 5 (35.7%) | 9 (64.3%) | |
| Moderately differentiated | 34 | 12 (35.3%) | 22 (64.7%) | |
| Poorly differentiated | 27 | 15 (55.6%) | 12 (44.4%) | |
| Estrogen receptor α * | 74 | 0.000 | ||
| ERα-negative | 24 | 18 (75.0%) | 6 (25.0%) | |
| ERα-positive | 50 | 14 (28.0%) | 36 (72.0%) | |
| Progesterone receptor * | 74 | 0.034 | ||
| PR-negative | 35 | 20 (57.1%) | 15 (42.9%) | |
| PR-positive | 39 | 12 (30.8%) | 27 (69.2%) | |
| Her2/neu * | 65 | 1.000 | ||
| Her2-negative | 62 | 29 (46.8%) | 33 (53.2%) | |
| Her2-positive | 3 | 2 (66.7%) | 1 (33.3%) | |
| Ki67 * | 63 | 0.062 | ||
| Low | 50 | 19 (38.0%) | 31 (62.0%) | |
| High | 13 | 9 (69.2%) | 4 (30.8%) | |
| Molecular Subtype * | 67 | 0.001 | ||
| Luminal A | 30 | 6 (20.0%) | 24 (80.0%) | |
| Luminal B | 15 | 7 (46.7%) | 8 (53.3%) | |
| Her2-positive | 3 | 2 (66.7%) | 1 (33.3%) | |
| TNBC | 19 | 14 (77.8%) | 4 (22.2%) | |
* Several cases were excluded from that analysis due by missing information such as tumor size (1), lymph node metastasis (1), TNM stage (1), Elston grade (2), estrogen receptor α (3), progesterone receptor (3), Her2/neu (12), Ki-67 (14), and molecular subtype (10). RPRM, Reprimo.